An unknown buyer entered into an agreement to acquire TetraPharma Ltd. from Instadose Pharma Corp. for $0.0001 million.
All shareholders of Instadose Pharma will be provided with the opportunity to exchange their presently held shares of common stock of Instadose Pharma for newly issued shares of common stock of TetraPharma on a one-for-one basis. Instadose Canada will continue its own business operations as usual.
As of July 6, 2023, Instadose Pharma has secured Shareholder Approval. The closing of this transaction shall take place on the 21st calendar day after the date when Instadose Pharma files with the U.S. Securities and Exchange Commission an information statement pursuant.